Professor Caroline Dive is internationally renowned for advancing circulating biomarker research, with a strong focus on circulating tumor cells (CTCs), particularly in lung cancer. She leads the world-class Clinical and Experimental Pharmacology Group (>50 staff) at the Cancer Research UK Manchester Institute, coordinating activities of scientists, bioinformaticians and clinicians. She has validated and implemented pharmacodynamic, prognostic and predictive biomarkers in clinical trials, working in tandem with clinical researchers and the Christie NHS Foundation Trust Cancer Treatment Centre. She has transformed the field of biomarker research and early clinical trial activities in the UK; her team has integrated reproducible protocols for the molecular profiling of CTCs into clinical trials, enhanced sample analysis for multi-site trials, and developed methods for circulating free DNA and CTC analysis from the same blood sample. She developed unique xenotransplantation models using CTCs enriched from small cell lung cancer patients' blood samples, providing a fully tractable system for therapy testing and understanding drug resistance mechanisms, a landmark development in the field. She plays a significant role within Cancer Research UK-funded TRACERx consortium, a pioneering study of intratumoural heterogeneity and evolution of non-small cell lung cancer, where she directs the CTC analysis within the consortium and is developing the first NSCLC CTC Biobank worldwide. She is the Manchester lead of the CRUK Lung Cancer Centre of Excellence, a partnership with University College London. Dive chairs the Biomarkers Expert Review Panel for CRUK and sits on their Science Committee.
Prof. Dive has received recognition in terms of international prizes, most notably the CRUK Translational Research Prize in 2011 and the Pasteur-Weizmann/Servier International Prize in 2012 for minimally invasive biomarkers to aid management of cancer patients. She is regularly asked to speak on lung cancer CTCs at international meetings, exemplified most recently at the AACR Precision Medicine series on drug resistance (Orlando, June 2014), the EACR annual conference in Munich (July 2014) and the AACR Annual Meeting in Philadelphia in 2015.